Demonstrate non-inferiority of GSK Biologicals' Tritanrix-HepB/Hib-MenAC vs Tritanrix-HepB/Hiberix with respect to anti-HBs immune response, when given to healthy infants at 6, 10 and 14 wks age, after a birth dose of hepatitis B vaccine.

Trial Profile

Demonstrate non-inferiority of GSK Biologicals' Tritanrix-HepB/Hib-MenAC vs Tritanrix-HepB/Hiberix with respect to anti-HBs immune response, when given to healthy infants at 6, 10 and 14 wks age, after a birth dose of hepatitis B vaccine.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2011

At a glance

  • Drugs Hib-DTP-hepatitis B-meningococcal vaccine groups A and C conjugate (Primary) ; Hib-DTP hepatitis B vaccine (Tritanrix-HepB/Hiberix); Meningococcal vaccine groups A C Y W-135 polysaccharide
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal infections; Pertussis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 30 Sep 2011 Actual initiation date (April 2006) added as reported by ClinicalTrials.gov.
    • 09 Oct 2008 Trial centres updated from NCT.
    • 09 Oct 2008 Checked against ClinicalTrials.gov record - last updated 9 Oct 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top